Rearranged during transfection (RET) is a protooncogene that encodes for receptor tyrosine
kinase with downstream effects on multiple cellular pathways. Activating RET alterations can …

Methods: A literature search for randomized phase 2/3 trials on the treatment of early-stage
NSCLC was performed based on PubMed and the content on major oncology congresses …

Tumor‐agnostic therapies represent a paradigm shift in oncology by altering the traditional
means of characterizing tumors based on their origin or location. Instead, they zero in on …

The LIBRETTO-001 trial demonstrated the activity of the selective rearrangement during
transfection (RET) inhibitor selpercatinib in advanced RET fusion-positive non-small cell …

During the last 2 decades, the understanding of non-small cell lung cancer (NSCLC) has
evolved from a purely histologic classification system to a more complex model synthesizing …

In the era of precision medicine, with the deepening of the research on malignant tumor
driving genes, clinical oncology has fully entered the era of targeted therapy. For non-small …

Background Cancer recurrence remains a significant problem, and most postoperative
recurrences of non-small cell lung cancer (NSCLC) develop within 5 years after resection …

The incidences of central nervous system (CNS) metastasis among newly diagnosed
treatment-naive patients with RET-positive (+) NSCLC enrolled into the registrational …

Selective RET inhibitors have shown promise in thyroid cancer (TC) and nonsmall cell lung
cancer (NSCLC) harboring RET fusions on next-generation sequencing (NGS), although …

The importance of uncommon/rare oncogenic drivers in non‐small cell lung cancer
(NSCLC) was underscored during the 20th China Lung Cancer Summit. These drivers …